Clinical trial
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic…
NCT00405743 · Clavis Pharma, Industry · Completed
Key facts
| NCT number | NCT00405743 |
|---|---|
| Title | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies |
| Official title | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies |
| Lead sponsor | Clavis Pharma, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies, AML |
| Intervention type | Drug |
| Interventions | CP-4055 |
| Enrollment | 153 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Nov 30, 2006 |
| Last update posted | Sep 18, 2013 |
| Countries | France, Germany, Italy, Norway, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: